Table 2. Characteristics of References in Support of Commenter Testimony.
| Characteristic | No. (%) |
|---|---|
| Totala | 641 |
| Observational, noninterventional study | 193 (30.1) |
| Randomized clinical trial, No. of participants | |
| <50 | 30 (4.7) |
| 50-99 | 54 (8.4) |
| 100-199 | 57 (8.9) |
| ≥200 | 56 (8.7) |
| Nonrandomized interventional trial, No. of participants | |
| <50 | 2 (0.3) |
| 50-99 | 1 (0.2) |
| 100-200 | 3 (0.5) |
| ≥200 | 2 (0.3) |
| Guideline | 35 (5.4) |
| Cost-effectiveness study | 25 (3.9) |
| Opinion | 8 (1.2) |
| Systematic review or meta-analysis | 58 (9.0) |
| US Food and Drug Administration documents | 6 (0.9) |
| Other | 105 (16.4) |
| Non-English | 4 (0.6) |
| Unknown (article not found) | 2 (0.3) |
a
A total of 641 references cited by 41 of 195 public commenters (21.0%).